Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.15 USD | +2.39% | +3.06% | -5.67% |
Sales 2024 * | 99.02M 7.89B | Sales 2025 * | 181M 14.46B | Capitalization | 483M 38.5B |
---|---|---|---|---|---|
Net income 2024 * | -126M -10.05B | Net income 2025 * | -62M -4.94B | EV / Sales 2024 * | 4.31 x |
Net cash position 2024 * | 55.62M 4.43B | Net cash position 2025 * | 277M 22.09B | EV / Sales 2025 * | 1.13 x |
P/E ratio 2024 * |
-3.94
x | P/E ratio 2025 * |
-8.47
x | Employees | 200 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.65% |
Latest transcript on UroGen Pharma Ltd.
1 day | +2.39% | ||
1 week | +3.06% | ||
Current month | -5.67% | ||
1 month | -5.67% | ||
3 months | -11.95% | ||
6 months | +27.94% | ||
Current year | -5.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 02/01/19 | |
Dong Kim
DFI | Director of Finance/CFO | 47 | 31/07/21 |
Jason Smith
CMP | Compliance Officer | 52 | 08/09/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arie Belldegrun
CHM | Chairman | 74 | 30/09/12 |
Cynthia Butitta
BRD | Director/Board Member | 70 | 30/09/17 |
Fred Cohen
BRD | Director/Board Member | 67 | 15/05/17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +2.14% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 14.15 | +2.39% | 135,619 |
25/04/24 | 13.82 | -2.74% | 185,411 |
24/04/24 | 14.21 | -2.20% | 97,025 |
23/04/24 | 14.53 | +1.11% | 216,766 |
22/04/24 | 14.37 | +4.66% | 278,571 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.67% | 483M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- URGN Stock